High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-1723

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance ; volume:13 ; number:1 ; day:22 ; month:9 ; year:2022 ; pages:1-17 ; date:12.2022
Nature Communications ; 13, Heft 1 (22.9.2022), 1-17, 12.2022

Creator: Cortés-López, Mariela
Schulz, Laura
Enculescu, Mihaela
Paret, Claudia
Spiekermann, Bea
Quesnel-Vallières, Mathieu
Torres-Diz, Manuel
Unic, Sebastian
Busch, Anke
Orekhova, Anna
Kuban, Monika
Mesitov, Mikhail
Mulorz, Miriam M.
Shraim, Rawan
Kielisch, Fridolin
Faber, Jörg
Barash, Yoseph
Thomas-Tikhonenko, Andrei
Zarnack, Katharina
Legewie, Stefan
König, Julian

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-022-31818-y

URN: urn:nbn:de:101:1-2022120921240849553524

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Cortés-López, Mariela
Schulz, Laura
Enculescu, Mihaela
Paret, Claudia
Spiekermann, Bea
Quesnel-Vallières, Mathieu
Torres-Diz, Manuel
Unic, Sebastian
Busch, Anke
Orekhova, Anna
Kuban, Monika
Mesitov, Mikhail
Mulorz, Miriam M.
Shraim, Rawan
Kielisch, Fridolin
Faber, Jörg
Barash, Yoseph
Thomas-Tikhonenko, Andrei
Zarnack, Katharina
Legewie, Stefan
König, Julian
SpringerLink (Online service)

Other Objects (12)

$Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy$

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Decoding cancer-relevant splicing networks in CD19 and MST1R

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy

An intragenic mutagenesis strategy in Physcomitrella patens to preserve intron splicing

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39

$Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy$

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Decoding cancer-relevant splicing networks in CD19 and MST1R

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy

An intragenic mutagenesis strategy in Physcomitrella patens to preserve intron splicing

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39

$Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy$

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Decoding cancer-relevant splicing networks in CD19 and MST1R

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy

An intragenic mutagenesis strategy in Physcomitrella patens to preserve intron splicing

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Decoding cancer-relevant splicing networks in CD19 and MST1R

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy

An intragenic mutagenesis strategy in Physcomitrella patens to preserve intron splicing

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Decoding cancer-relevant splicing networks in CD19 and MST1R

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy

An intragenic mutagenesis strategy in Physcomitrella patens to preserve intron splicing

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Decoding cancer-relevant splicing networks in CD19 and MST1R

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy

An intragenic mutagenesis strategy in Physcomitrella patens to preserve intron splicing

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies

Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39

Related objects

Reset password